Association between transit-amplifying signature and outcomes of patients treated with anti-epidermal growth factor receptor (EGFR) therapy in colorectal cancer
Abstract
Background null In CRC, the transit-amplifying (TA) subtype is enriched for tumours sensitive to anti-EGFR agents. At the same time, the presence of TA gene signature in tumours belonging to other subtypes may suggest potential anti-EGFR benefit. Hence, we evaluated the association between the TA signature (presence - class 1; absence - class 2) and outcomes in CRC patients (pts) treated with anti-EGFR therapy. null null null Methods null...
Paper Details
Title
Association between transit-amplifying signature and outcomes of patients treated with anti-epidermal growth factor receptor (EGFR) therapy in colorectal cancer
Published Date
Oct 1, 2019
Journal
Volume
30
Pages
v201 - v202
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History